Tridek-One

Tridek-One is a preclinical-stage biotech developing a novel class of immune-modulating therapies targeting the CD31 (PECAM-1) inhibitory checkpoint. The company's core technology is a bispecific antibody platform that combines anti-CD31 agonism with cell-specific targeting via ITAM receptors, aiming to deliver localized immunosuppression with a reduced risk of systemic side effects. Financed by leading European venture capital firms, the company has raised approximately €11 million in equity and secured €1.9 million in non-dilutive Deeptech financing. Tridek-One is led by a seasoned management team with deep expertise in biologics development and immunology.

Platform for developing bispecific antibodies that combine an agonistic anti-CD31 arm with a cell-specific ITAM receptor-targeting arm. This enables localized, cell-specific inhibition of immune cell activation via CD31's ITIM-mediated signaling, aiming to restore immune balance with reduced systemic immunosuppression.

The autoimmune therapeutic landscape is highly competitive, dominated by blockbuster biologics (e.g., TNF inhibitors, IL-6/IL-17/IL-23 inhibitors) and a growing number of small molecules (JAK inhibitors). Tridek-One's approach is differentiated by targeting the inhibitory CD31 checkpoint, a pathway distinct from cytokine blockade. Competitors include companies developing other co-inhibitory receptor agonists (e.g., BTLA, TIGIT), but CD31 agonism appears to be a unique strategy.